Sage Therapeutics (NASDAQ:SAGE) Hits New 12-Month Low at $16.48

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $16.48 and last traded at $16.58, with a volume of 794537 shares traded. The stock had previously closed at $17.15.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SAGE shares. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, February 15th. Morgan Stanley lifted their price objective on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. Royal Bank of Canada raised their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a "sector perform" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. raised their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an "overweight" rating in a research note on Tuesday, March 26th. Finally, HC Wainwright raised their target price on shares of Sage Therapeutics from $25.00 to $28.00 and gave the company a "neutral" rating in a research note on Thursday, February 15th. Fifteen analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Sage Therapeutics has an average rating of "Hold" and an average target price of $41.00.

Sage Therapeutics Price Performance

The firm has a market capitalization of $996.62 million, a price-to-earnings ratio of -1.83 and a beta of 0.86. The firm's fifty day moving average is $21.79 and its 200 day moving average is $21.24.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. The business had revenue of $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm's quarterly revenue was up 2621.5% compared to the same quarter last year. During the same period last year, the company posted ($2.47) earnings per share. Equities research analysts forecast that Sage Therapeutics, Inc. will post -6.11 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new stake in shares of Sage Therapeutics in the third quarter worth $105,976,000. Goldman Sachs Group Inc. lifted its stake in shares of Sage Therapeutics by 252.9% in the second quarter. Goldman Sachs Group Inc. now owns 1,106,276 shares of the biopharmaceutical company's stock worth $35,733,000 after buying an additional 792,819 shares during the last quarter. State Street Corp lifted its stake in shares of Sage Therapeutics by 30.8% in the first quarter. State Street Corp now owns 2,835,356 shares of the biopharmaceutical company's stock worth $93,850,000 after buying an additional 666,826 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Sage Therapeutics by 13.7% in the third quarter. BlackRock Inc. now owns 4,822,063 shares of the biopharmaceutical company's stock worth $188,833,000 after buying an additional 580,250 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Sage Therapeutics by 145.5% in the third quarter. Morgan Stanley now owns 863,932 shares of the biopharmaceutical company's stock worth $17,780,000 after buying an additional 512,021 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.